Motivista (CT-155) is a prescription digital therapeutic indicated for the treatment of negative symptoms of schizophrenia as an adjunct to clinician-managed outpatient care, including antipsychotic therapy, in patients 18 years of age and older with clinically stable positive symptoms. Motivista received 510(k) clearance from the U.S. Food and Drug Administration (FDA)in July 2026.

Motivista has achieved all development milestones and generated supportive data across multiple clinical learning studies, leading to the initiation of the CONVOKE registrational clinical trial in May 2023. This robust phase 3 randomized, controlled trial concluded in June 2025, with the successful achievement of the primary endpoint announced in August 2025.

Motivista is the first therapeutic developed as part of the collaboration between Click Therapeutics and Boehringer Ingelheim, which kicked off in September 2020. The collaboration was recently modified in April 2026 to transfer full control of Motivista to Click alongside Boehringer's Series D investment in the company. 

Safety Information

Motivista is not designed to treat patients who present a serious suicide risk such as patients with active suicidal ideation with method or intent within the last 3 months or patients with suicidal behavior within the last 6 months or presentation with suicide risk (based on opinion of the clinician). Motivista is not designed to treat patients with unmanaged positive symptoms. Motivista is not intended to be used as a standalone therapy. It is meant to be used as an adjunct to clinician-managed pharmacotherapy for schizophrenia. Motivista does not replace or substitute the patient’s medication, including medication for treatment of schizophrenia. Patients should continue their current treatment as directed. Motivista cannot send alerts or warnings to the prescriber. If patients feel that their schizophrenia symptoms are worsening or if they have feelings or thoughts of harming themselves or others, they should stop using the app and contact a healthcare provider, dial 988 (for mental health emergencies) or 911 (for medical emergencies), or go to the nearest emergency room immediately. A possibly-related Treatment Emergent Adverse Event (TEAE) was observed during Motivista’s pivotal clinical study. Two events of "psychotic disorder" were considered possibly related to Motivista in a single participant, though neither led to study discontinuation.

The safety and effectiveness of Motivista have not been evaluated in: patients with positive symptoms that are not well-controlled; patients not taking antipsychotic medication; patients with severe cognitive impairment who are unable to use the app independently; patients who present a serious suicide risk, or; patients less than 18 years of age. Motivista is not intended to be used for acute symptoms of schizophrenia. 

There are no contraindications to using Motivista.